NCT06073730 2023-10-10
Viale-a
The Second Affiliated Hospital of Kunming Medical University
Phase 3 Unknown
Clinical Trials
56 trialsNCT05816746 2023-05-09
Decitabine and Anti-PD-1 in R/R DLBCL
Chinese PLA General Hospital
Phase 2 Unknown
NCT05805072 2023-05-06
Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients
The First Affiliated Hospital of Soochow University
Phase NA Unknown
NCT03855371 2022-11-04
PANDA-T0
Ruijin Hospital
Phase 1 Unknown
NCT05382390 2022-05-19
Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen in Acute Myeloid Leukemia: Study Protocol for a Randomized Controlled Trial
Shengjing Hospital
Phase 3 Unknown
NCT05362942 2022-05-05
Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia
Beijing 302 Hospital
Phase 2 Unknown
NCT05320640 2022-04-11
Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid Tumors
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT05265962 2022-03-04
Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade
The First Affiliated Hospital of Zhengzhou University
Phase 2 Unknown
NCT05258799 2022-02-28
Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen for Elderly Patients With Acute Myeloid Leukemia: A Phase II Single-Arm Multicenter Study
Shengjing Hospital
Phase NA Unknown
NCT05137886 2021-12-17
PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Unknown
NCT04752527 2021-11-15
Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT03257241 2021-10-01
PALG-AML1/2016
Polish Adult Leukemia Group
Phase 3 Unknown
NCT03467178 2021-09-05
MITO29
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Unknown
NCT03080766 2021-04-28
The Use of Decitabine as Induction Therapy for Acute Myeloid Leukemia With Complex and/or Monosomal Karyotype
The University of Hong Kong
Phase 2 Unknown
NCT03530085 2020-12-22
Dec+Flu+Bu Conditioning Regimen for Elderly AML in CR Undergoing Allo-HSCT
Nanfang Hospital, Southern Medical University
Phase 2/3 Unknown
NCT04553393 2020-12-04
Decitabine-primed Tandem CD19/CD20 CAR T Cells Plus Epigenetic Agents in Aggressive r/r B-NHL With Huge Tumor Burden
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT04025593 2020-11-19
Biomarker Guided Treatment in DLBCL
Ruijin Hospital
Phase 2 Unknown
NCT04582604 2020-10-20
Ruxolitinib and Decitabine for High Risk Hematological Malignancies
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT04454580 2020-09-16
Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy
Ospedale Maggiore Di Trieste
Unknown
NCT04541277 2020-09-09
Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive Chemotherapy
Chinese PLA General Hospital
Phase 2 Unknown
NCT04514081 2020-08-18
The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma.
Chinese PLA General Hospital
Phase 2 Unknown
NCT04233294 2020-08-14
Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma
Chinese PLA General Hospital
Phase 2 Unknown
NCT04510610 2020-08-12
Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Chinese PLA General Hospital
Phase 2/3 Unknown
NCT04279379 2020-05-07
Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma
Beijing Tongren Hospital
Phase 2 Unknown
NCT03417427 2020-04-27
A Clinical Trail of Demethylation Drug Combined With Chemotherapy in Intermediate-risk AML
Nanfang Hospital, Southern Medical University
Phase 2 Unknown
NCT04353479 2020-04-20
Combined PD1 Inhibitor and Decitabine in Elderly Patients With Relapse and Refractory Acute Myeloid Leukemia
Shanghai Jiao Tong University School of Medicine
Phase 2 Unknown
NCT04337606 2020-04-07
Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT02951728 2020-03-11
DR-CHOP
Ruijin Hospital
Phase 1/2 Unknown
NCT04292769 2020-03-03
Clinical Study of DC-CIK Cells as a Post-remission Treatment for Malignant Tumors
Chinese PLA General Hospital
Phase 3 Unknown
NCT02272478 2020-01-23
AML18
Cardiff University
Phase 2/3 Unknown
NCT04168138 2019-11-19
D-CTAG in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients
Shengjing Hospital
Phase NA Unknown
NCT04123392 2019-10-10
Decitabine + BUCY vs BUCY Conditioning Regimen for TP53+ Myeloid Tumors Undergoing Allo-HSCT
Nanfang Hospital, Southern Medical University
Phase 2/3 Unknown
NCT04098653 2019-09-23
Decitabine + BUCY vs BUCY Conditioning Regimen for Myeloid Tumors Undergoing Allo-HSCT
Nanfang Hospital, Southern Medical University
Phase 2/3 Unknown
NCT04087967 2019-09-12
Study of DAC Combined With HAAG Regimen in Newly Diagnosed Younger AML Patients
The First Affiliated Hospital of Soochow University
Phase 3 Unknown
NCT04083911 2019-09-10
Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60
The First Affiliated Hospital of Soochow University
Phase 3 Unknown
NCT04049344 2019-08-08
Decitabine Combined With Oxaliplatin in Patients With Advanced Renal Cell Carcinoma
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT03799224 2019-05-29
Decitabine Plus mBU/CY Preconditioning for Relapse/Refractory Acute Leukemia
Peking University People's Hospital
Phase 2/3 Unknown
NCT03250962 2019-04-01
SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma
Chinese PLA General Hospital
Phase 2 Unknown
NCT03771222 2018-12-13
Prophylactic Donor Lymphocyte Infusion After Allo-PBSCT for Patients With Very High-risk Hematologic Malignancies
Chinese PLA General Hospital
Phase 2 Unknown
NCT03558412 2018-09-14
A Clinical Trial of Decitabine in Relapsed or Refractory T-lymphoblastic Lymphoma
Zhengzhou University
Phase 4 Unknown
NCT03579082 2018-09-14
A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma
Zhengzhou University
Phase 4 Unknown
NCT03553537 2018-06-12
Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma
Southwest Hospital, China
Phase 3 Unknown
NCT03381781 2018-01-04
Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations
Ruijin Hospital
Phase 2 Unknown
NCT03356080 2017-11-29
DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess
Shanghai Tong Ren Hospital
Phase 2 Unknown
NCT03256071 2017-08-21
Low Dose Decitabine + Modified BUCY Conditioning Regimen for High Risk Acute Myeloid Leukemia Undergoing Allo-HSCT
The First Affiliated Hospital of Soochow University
Phase 2/3 Unknown
NCT03026842 2017-01-20
Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Acute Myeloid Leukemia With t(8;21)
The First Hospital of Jilin University
Phase 4 Unknown
NCT02985372 2016-12-07
Decitabine in Combination With Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia
Shandong University
Phase 3 Unknown
NCT01758367 2016-08-31
Decitabine Followed by Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloblastic Leukemia(AML) After Allogeneic Stem Cell Transplantation
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT02698124 2016-03-07
PURPLE-D
Ulsan University Hospital
Unknown
NCT02685228 2016-02-18
SLOWDOSE001
The First Hospital of Jilin University
Phase NA Unknown